Literature DB >> 30225768

Diagnosis and Management of Genetic Iron Overload Disorders.

William C Palmer1, Prakash Vishnu2, William Sanchez3, Bashar Aqel4, Doug Riegert-Johnson5, Leigh Ann Kenda Seaman6, Andrew W Bowman7, Candido E Rivera2.   

Abstract

Iron overload disorders lead to excess iron deposition in the body, which can occur as a result of genetic or secondary causes. Genetic iron overload, referred to as hereditary hemochromatosis, may present as a common autosomal recessive mutation or as one of several uncommon mutations. Secondary iron overload may result from frequent blood transfusions, exogenous iron intake, or certain hematological diseases such as dyserythropoietic syndrome or chronic hemolytic anemia. Iron overload may be asymptomatic, or may present with significant diseases of the liver, heart, endocrine glands, joints, or other organs. If treated appropriately prior to end-organ damage, life expectancy has been shown to be similar compared to matched populations. Alongside clinical assessment, diagnostic studies involve blood tests, imaging, and in some cases liver biopsy. The mainstay of therapy is periodic phlebotomy, although oral chelation is an option for selected patients.

Entities:  

Keywords:  hemochromatosis; iron overload

Mesh:

Year:  2018        PMID: 30225768      PMCID: PMC6258594          DOI: 10.1007/s11606-018-4669-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  34 in total

1.  Heterozygosity for the H63D mutation in the hereditary hemochromatosis (HFE) gene may lead into severe iron overload in beta-thalassemia minor: observations in a thalassemic kindred.

Authors:  G J Ruiz-Argüelles; J Garcés-Eisele; V Reyes-Núñez; J Sánchez-Anzaldo; G J Ruiz-Delgado; C Jiménez-González; B Carrera
Journal:  Rev Invest Clin       Date:  2001 Mar-Apr       Impact factor: 1.451

Review 2.  Non-HFE hemochromatosis.

Authors:  Antonello Pietrangelo
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

3.  SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent.

Authors:  James C Barton; Ronald T Acton; Pauline L Lee; Carol West
Journal:  Blood Cells Mol Dis       Date:  2007-05-09       Impact factor: 3.039

4.  Hemochromatosis and iron-overload screening in a racially diverse population.

Authors:  Paul C Adams; David M Reboussin; James C Barton; Christine E McLaren; John H Eckfeldt; Gordon D McLaren; Fitzroy W Dawkins; Ronald T Acton; Emily L Harris; Victor R Gordeuk; Catherine Leiendecker-Foster; Mark Speechley; Beverly M Snively; Joan L Holup; Elizabeth Thomson; Phyliss Sholinsky
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

Review 5.  Free heme toxicity and its detoxification systems in human.

Authors:  Sanjay Kumar; Uday Bandyopadhyay
Journal:  Toxicol Lett       Date:  2005-04-07       Impact factor: 4.372

6.  Clinical evaluation of a hemochromatosis next-generation sequencing gene panel.

Authors:  Matthew B Lanktree; Bekim Sadikovic; John S Waye; Alexander Levstik; Bruce B Lanktree; Jovana Yudin; Mark A Crowther; Guillaume Pare; Paul C Adams
Journal:  Eur J Haematol       Date:  2016-11-11       Impact factor: 2.997

7.  Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes.

Authors:  Raymond Cheng; James C Barton; Elizabeth D Morrison; Pradyumna D Phatak; Edward L Krawitt; Stuart C Gordon; Kris V Kowdley
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

8.  HFE C282Y homozygotes are at increased risk of breast and colorectal cancer.

Authors:  Nicholas J Osborne; Lyle C Gurrin; Katrina J Allen; Clare C Constantine; Martin B Delatycki; Christine E McLaren; Dorota M Gertig; Gregory J Anderson; Melissa C Southey; John K Olynyk; Lawrie W Powell; John L Hopper; Graham G Giles; Dallas R English
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

Review 9.  Dietary iron overload in the African and hepatocellular carcinoma.

Authors:  Michael C Kew; George A Asare
Journal:  Liver Int       Date:  2007-08       Impact factor: 5.828

10.  Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Bruce R Bacon; Paul C Adams; Kris V Kowdley; Lawrie W Powell; Anthony S Tavill
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

View more
  3 in total

1.  CoDysAn: A Telemedicine Tool to Improve Awareness and Diagnosis for Patients With Congenital Dyserythropoietic Anemia.

Authors:  Cristian Tornador; Edgar Sánchez-Prados; Beatriz Cadenas; Roberta Russo; Veronica Venturi; Immacolata Andolfo; Ines Hernández-Rodriguez; Achille Iolascon; Mayka Sánchez
Journal:  Front Physiol       Date:  2019-09-13       Impact factor: 4.566

2.  Feasibility study and direct extraction of endogenous free metallic cations combining hemodialysis and chelating polymer.

Authors:  Marco Natuzzi; Coralie Grange; Thomas Gréa; Thomas Brichart; Axel Aigle; Denise Bechet; Benoit Hautefeuille; Eloise Thomas; Jean-Yves Ayoub; Jeanne-Marie Bonnet; Vanessa Louzier; Bernard Allaouchiche; Aymeric Couturier; Alexandra Montembault; Paula Nunes de Oliveira; Laurent David; François Lux; Olivier Tillement
Journal:  Sci Rep       Date:  2021-10-07       Impact factor: 4.379

3.  Plasma proteome profiling combined with clinical and genetic features reveals the pathophysiological characteristics of β-thalassemia.

Authors:  Na Li; Peng An; Jifeng Wang; Tingting Zhang; Xiaoqing Qing; Bowen Wu; Lang Sun; Xiang Ding; Lili Niu; Zhensheng Xie; Mengmeng Zhang; Xiaojing Guo; Xiulan Chen; Tanxi Cai; Jianming Luo; Fudi Wang; Fuquan Yang
Journal:  iScience       Date:  2022-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.